Michael Dowling to Step Down as Northwell Health President & CEO, to Be Succeeded by Northwell Executive VP John D'Angelo, MD
NEW HYDE PARK, N.Y., May 14, 2025--(BUSINESS WIRE)--Northwell Health, New York's largest non-for-profit health care provider and private employer, today announced that after serving as Northwell's first president and chief executive officer for more than 23 years, Michael J. Dowling will step down effective October 1, 2025 and transition to the role of CEO Emeritus, where he will serve in an advisory capacity, supporting the advancement of key public health initiatives, and focusing on teaching and writing.
Mr. Dowling's transition marks the end of an extraordinary tenure characterized by significant growth, industry innovation, and a steadfast commitment to enhancing health for all. Over the past two decades, his visionary leadership has transformed Northwell from a network of Long Island-based hospitals into one of the nation's ten largest health systems, renowned for its clinical, academic, and research excellence. Under his leadership, Northwell became New York State's first integrated health system in 1992 and now includes 28 hospitals across New York and Connecticut, employing 104,000 individuals, with over 14,000 affiliated physicians, 1,000 care locations, and a comprehensive network of home care, rehabilitation, and end-of-life services.
As president and CEO of Northwell, Michael Dowling spearheaded the system's remarkable expansion, championing investments in research, leading to the growth of the Feinstein Institutes for Medical Research and positioning Northwell at the forefront of bioelectronic medicine. His dedication to innovative medical education through the Zucker School of Medicine, the Hofstra-Northwell School of Nursing, and Northwell's Center for Learning and Innovation has cultivated the next generation of healthcare professionals. Additionally, Mr. Dowling has taken a leadership role in addressing gun violence, the leading cause of death among children in the United States, recognizing it as a critical healthcare issue. He has mobilized over 60 healthcare CEOs nationwide to support gun violence prevention. For 18 consecutive years, he has been named to Modern Healthcare magazine's list of the "100 Most Influential People in Healthcare," achieving the magazine's #1 ranking in 2022.
After an extensive nationwide search, and confirmed in a unanimous vote, Northwell's Board of Trustees has appointed John D'Angelo, MD, who currently serves as executive vice president of the health system's central region, to succeed Mr. Dowling as president and CEO in October. Dr. D'Angelo began his more than 25-year tenure at Northwell as an emergency medicine physician at Glen Cove Hospital before advancing into health system-wide clinical and administrative leadership roles.
"It has been an extraordinary privilege to lead Northwell through a period of unprecedented growth and clinical transformation that has enabled our team members to make a meaningful difference and improve the lives of the tens of millions of patients and families who we've cared for over the last 25 years," said Mr. Dowling. "In Dr. D'Angelo, the Board of Trustees has selected a tremendous leader who will lead Northwell to greater heights. John is someone who understands and champions Northwell's unique and differentiated culture and his clinical and operational acumen coupled with skills as a decisive and collaborative leader will enable Northwell to raise the bar on the quality of care we deliver to the communities we serve in New York and Connecticut. I look forward to partnering with Dr. D'Angelo in the coming months to help ensure a seamless transition to what will be an exciting new chapter in the 33-year history of Northwell."
"I am humbled and honored to be selected to succeed Michael Dowling as Northwell President and CEO. I am committed to build on his unparalleled legacy and vision that grew Northwell from a Long Island based health system into a regional and national health care leader," said Dr. D'Angelo. "Healthcare is a calling. Every minute of every day we have an opportunity to change someone's life for the better, and I look forward to leading our more than 100,000 team members who contribute to this critically important mission. Together, we will continue advancing better health for all."
As president of Northwell's central region, Dr. D'Angelo leads a dynamic healthcare network serving 2.8 million residents in western Nassau County and Queens, a network that includes 6 hospitals, over 270 ambulatory practice locations, and a dedicated team of 24,000 employees. During the COVID-19 pandemic, Dr. D'Angelo was at the forefront, orchestrating Northwell's operational response and later becoming Chief of Integrated Operations charged with streamlining system operations in the post-pandemic era.
Before this role, Dr. D'Angelo was the senior vice president of Northwell's Emergency Medicine service line, where he managed 18 emergency departments and network of 60+ urgent care centers, serving 1.5 million patients annually. With nearly three decades of experience as an emergency medicine physician, Dr. D'Angelo possesses a deep understanding of clinical care delivery, quality, process improvement, and operational management.
"The Northwell Board of Trustees is enormously grateful for Michael Dowling's extraordinary tenure, and we are delighted to name Dr. D'Angelo as our next CEO," said Board Chair Margaret Crotty. "Dr. D'Angelo is an experienced administrator, leading a region that itself would rank among the country's largest health systems. He is a trusted mentor for so many Northwell leaders; a respected manager who inspires his team to consistently drive results; and a strategic leader who deploys technology toward the best health outcomes. John clearly stood out among an impressive slate as the best person to bring Northwell into a new era of care."
About Northwell Health
Northwell is the largest not-for-profit health system in the Northeast, serving residents of New York and Connecticut with 28 hospitals, more than 1,000 outpatient facilities, 22,000 nurses and over 20,000 physicians. Northwell cares for more than three million people annually in the New York metro area, including Long Island, the Hudson Valley, western Connecticut and beyond, thanks to philanthropic support from our communities. Northwell is New York State's largest private employer with over 104,000 employees – including members of Northwell Health Physician Partners and Nuvance Health Medical Practices – who are working to change health care for the better. Northwell is making breakthroughs in medicine at the Feinstein Institutes for Medical Research. Northwell is training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, X, Instagram and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250512723577/en/
Contacts
Barbara OsbornVP, Public RelationsBosborn@northwell.edu
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Kaiser cuts dozens of Bay Area jobs in latest round of statewide layoffs
SAN FRANCISCO (KRON) — Kaiser cut dozens of jobs across the Bay Area this week in the latest round of statewide layoffs from the health care provider. The layoffs will impact personnel at Kaiser Foundation Hospitals across the state, according to a filing with the Employment Development Department. In the Bay Area, a total of 40 jobs will be cut with layoffs impacting facilities in Oakland, Berkeley, Fremont, Pleasanton, San Francisco, and Vallejo. Statewide, a total of 55 jobs will be cut with layoffs impacting workers in Harbor City, Pasadena, Walnut, Fair Oaks, Los Angeles County, Yorba Linda, Irvine, Roseville, and San Diego. What's behind the ongoing Bay Area tech layoffs? 'Nobody is safe,' expert says The job cuts were announced on Monday and took immediate effect. All of the layoffs were described as permanent in state filings. The latest layoffs follow a previous round of job cuts at Kaiser back in April when the Oakland-based health care provider cut 40 jobs across the state, including 17 in the Bay Area. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Coal mines on Alberta's eastern slopes could push fishery 'beyond recovery': study
CALGARY — Old coal mines on the eastern slopes of the Alberta Rockies are leaching chemicals that are poisoning the fish downstream, says a new study by Alberta government scientists. It also suggests any new coal developments could result in "population collapse" of fish species in a nearby lake. The findings were made in a provincial government study posted online May 27. The paper is awaiting peer review. The scientists who authored it were not made available to speak to reporters. The other authors not employed by the province did not respond to requests for comment. Alberta has responded to the study with an advisory saying people should consider "limiting consumption" of three fish species drawn from Crowsnest Lake, a fishing spot downstream from the coal mines. Those species were found to have dangerously high levels of selenium, a mineral found in coal-rich deposits, in their body tissue. The authors write the study shows that "biological impacts of (mountaintop removal) coal mining can persist long after mining operations end." They suggest that "any further coal mine development may well push the Crowsnest fishery beyond sustainability.' The study comes after the Alberta Energy Regulator, or AER, granted an Australia-based coal company permission to start a controversial coal exploration on the eastern slopes. The project was initially rejected in 2021 when a panel ruled the likely environmental effects on fish and water quality outweighed potential economic benefits. But the regulator said last month it's possible there will be runoff from the nearby pit lake that Northback Holding Corp. is using. It ultimately concluded the project won't have any effect on the water quality downstream. The AER said that "out of an abundance of caution," Northback will have to comply with a directive for managing drilling waste in response to concerns over selenium. The new study measured selenium levels in fish from Crowsnest Lake, which is fed by creeks connected to Tent Mountain and Grassy Mountain – both former coal mine sites. Alberta has a fish tissue selenium guideline of four micrograms per gram. The authors write that every single fish sample analyzed exceeded this value. Average selenium concentrations were highest in Brown Trout, coming in at 18 micrograms per gram. The authors write that the selenium levels could lead to 'behavioural changes, physical symptoms ... respiratory issues, reproductive issues and ultimately population collapse." Accumulating fluid in body tissue or fin and tail damage are among other side effects. Most people are exposed to healthy levels of selenium through grains and flours, but Health Canada says elevated consumption can lead to hair loss, decreased cognitive function and gastrointestinal disorders. The high selenium concentrations can only be explained by "the incorporation of legacy coal mine pollution,' the authors write. The study goes on to say selenium levels in fish in Crowsnest Lake are similar to those found in water bodies near Fernie, B.C., that resulted in Teck Mining Company, which owned and operated a nearby mine, being forced in 2021 by B.C. provincial court to pay a $60 million fine – the largest fine ever imposed under the Fisheries Act. Fish populations in those mining-impacted streams were found in 2011 to have an average selenium concentration of 7.6 micrograms per gram. Nine years later, the adult westslope cutthroat population had suffered a 93 per cent decline, the study says. The authors conclude that factors including the emergence of Whirling Disease, drought conditions, high fishing activity -- and now high selenium levels in fish -- make the Crowsnest Lake and River "an especially vulnerable system.' 'Any new development of coal mining along the eastern slopes may well push the Crowsnest fishery beyond recovery,' they write. Colin Cooke, one of the authors, published a 2024 study that found a former coal mine in the Crowsnest River watershed was releasing selenium to fish at rates more than dozens of times higher than federal and provincial guidelines. Cooke is a senior aquatic scientist with the Alberta government, according to LinkedIn. Peter Doyle, CEO of Evolve Power Ltd., formerly Montem Resources Ltd., which previously sought to restart an old mine on Tent Mountain, said in an email that the company is complying with terms set out by the AER. "As reflected in other work by the author, there are numerous contributors to water quality in the Crowsnest River valley, not related to Tent Mountain, including changes in upstream conditions, changes in weathering rates and other anthropogenic changes in the watershed," Doyle wrote, referring to Cooke's 2024 study. That report notes those factors, among others, could be contributing to contaminant levels and concluded that coal mining activities in the Crowsnest River watershed "have been impacting ecosystems downstream for decades." Northback, in an email, wrote that Crowsnest Lake is unrelated to its Grassy Mountain project. "However, with our own project, Northback is committed to adhering to the highest environmental standards and ensuring a safe water supply." Ryan Fournier, press secretary for Alberta's environment ministry, deferred questions about monitoring and enforcement to the AER. He said the province is funding a series of studies and submitting them to peer-reviewed academic journals as the province revises its coal policy. He also said the authors were not available to speak to media because they "are not trained spokespeople." The AER told The Canadian Press that it has directed Evolve Power, the Tent Mountain owner, to submit a "selenium management plan proposal" that targets reductions in selenium in mine-affected water. Evolve was to submit that plan by July 31 of last year, but the AER said it granted the company an extension to March 31, 2026. The energy regulator also said that while selenium levels are elevated, "there is no evidence of non-compliance on monitoring or selenium management requirements at this time." The province announced in December it would allow coal mining to take place in Alberta under certain conditions. However, it exempted Northback and Evolve Power's projects from those rules because they were considered "advanced." Fisheries and Oceans Canada said in a statement that it doesn't comment on provincial permitting decisions and it hasn't been asked to review the local impacts to wildlife in the area. This report by The Canadian Press was first published June 6, 2025. Matthew Scace, The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine. With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty. This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. BANGKOK, June 06, 2025--(BUSINESS WIRE)--IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. As part of the congress, IBSA Derma will host a scientific symposium titled "The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line" scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead the session, focusing on the evolving approaches in regenerative aesthetic medicine, with particular attention to the clinical impact of hybrid cooperative complexes (HCCs) of hyaluronic acid and their role in tissue regeneration across different anatomical layers affected by aging. HCCs represent a new frontier in hyaluronic acid-based product formulation, made possible through NAHYCO® Technology, IBSA's patented thermal process that celebrates its 10th anniversary this year. This technological breakthrough is the foundation of the Profhilo® line and continues to be a milestone of IBSA Derma's innovation pathway. The Company's presence at IMCAS Asia is part of a broader strategic plan for expansion across the APAC region, an increasingly dynamic and high-potential market. In this context, IBSA Derma strengthened its regional presence last year with the opening of its regional hub in Singapore and the launch of a dedicated platform for Asian Key Opinion Leaders to share their clinical insights and expertise. "The strong growth we are experiencing in the APAC region stems from our solid collaboration with local distributors, which enable us to better understand the specific dynamics and cultural nuances of each market" – says Loy Derris, Business Development Director Dermoaesthetic Division North Asia. "Over the past 18 months, we have achieved remarkable results in countries such as Indonesia, Vietnam, Japan, and India, and we have recently entered the Thai market with great momentum. Looking ahead we are also looking enthusiastically toward promising new markets like Taiwan" – declares Magallon Riza Marie, Senior Strategic Marketing and Operational Lead Dermoaesthetic APAC Region. "Being at IMCAS Asia for the second year in a row is a valuable opportunity to strengthen our dialogue with physicians in the APAC Region and promote our concept of authentic beauty that embraces a holistic and overall wellness-oriented approach" – states Elisa Brozzelli, Brand Activation Manager Dermoaesthetic Division. IBSA Derma will also be present at Booth 8 - Level 2, where visitors can learn more about the latest solutions and innovations in aesthetic medicine. About IBSA IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA will celebrate the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,300 personnel worldwide. IBSA's growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people. About IBSA Derma IBSA has used its experience and expertise in the pharmaceutical field to branch out and develop medical devices for aesthetic medicine based on hyaluronic acid, thus creating a dedicated division: IBSA Derma. Through scientific expertise, continuous research, technological development and a modern production process, IBSA has become one of the leading pharmaceutical companies to produce hyaluronic acid for aesthetic medicine applications. IBSA Derma distinguishes itself in this vast market because it controls the entire product lifecycle, from the biofermentation production of the raw material to the ready-to-use final product in prefilled syringes. View source version on Contacts For further information: Giulia Drei, PR and Communication SpecialistDermoaesthetic Sign in to access your portfolio
